CAMBRIDGE, Mass., April 29 /PRNewswire-FirstCall/ --
Transkaryotic Therapies, Inc. (Nasdaq: TKTX) today announced that the company
will be participating at Deutsche Bank's 28th Annual Health Care Conference in
Baltimore, Maryland. TKT's presentation will be webcast live on Tuesday,
May 6, 2003 at 9:30 a.m. E.T. and may be accessed on the Internet at
http://www.tktx.com under the Investor Information section. The presentation will be
archived for 2 weeks.
About TKT
TKT is a biotechnology company developing and commercializing human
proteins for a broad range of diseases, with a major focus on rare genetic
diseases. TKT currently markets one product, Replagal(TM) (agalsidase alfa)
for the treatment of Fabry disease, in the European Union and certain other
countries. TKT is headquartered in Cambridge, Massachusetts and has a
majority-owned subsidiary in Sweden, TKT Europe-5S AB, which is responsible
for European sales and marketing activities for Replagal. Additional
information on TKT is available on the company's website at http://www.tktx.com.
Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
Contact:
Justine Koenigsberg
Director, Corporate Communications
(617) 349-0271
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine Koenigsberg, Director, Corporate
Communications of TKT, +1-617-349-0271
|
